Ensysce Biosciences
Founded Year
2003Stage
Reverse Merger | IPOTotal Raised
$14.19MMarket Cap
0.00BStock Price
0.80About Ensysce Biosciences
Ensysce Biosciences (NASDAQ: ENSC) (OTC: ENSCW) is focused on the use of fullerene carbon nanotubes for therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr. Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
Compete with Ensysce Biosciences?
Ensure that your company and products are accurately represented on our platform.
Expert Collections containing Ensysce Biosciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ensysce Biosciences is included in 3 Expert Collections, including Advanced Materials.
Advanced Materials
1,275 items
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Ensysce Biosciences Patents
Ensysce Biosciences has filed 6 patents.
The 3 most popular patent topics include:
- Dosage forms
- Drug delivery devices
- Prodrugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/1/2011 | 7/8/2014 | Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices | Grant |
Application Date | 7/1/2011 |
|---|---|
Grant Date | 7/8/2014 |
Title | |
Related Topics | Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices |
Status | Grant |
Latest Ensysce Biosciences News
Jan 25, 2023
News provided by Share this article Share this article NEW YORK, Jan. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, FFIE, ENSC, NVDA, and MULN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. SOURCE InvestorsObserver
Ensysce Biosciences Frequently Asked Questions (FAQ)
When was Ensysce Biosciences founded?
Ensysce Biosciences was founded in 2003.
Where is Ensysce Biosciences's headquarters?
Ensysce Biosciences's headquarters is located at 7946 Ivanhoe Avenue, La Jolla.
What is Ensysce Biosciences's latest funding round?
Ensysce Biosciences's latest funding round is Reverse Merger.
How much did Ensysce Biosciences raise?
Ensysce Biosciences raised a total of $14.19M.
Who are the investors of Ensysce Biosciences?
Investors of Ensysce Biosciences include Leisure Acquisition, Global Emerging Markets, National Institute on Drug Abuse and Texas Emerging Technology Fund.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.